US equities
|
NVDA
$238.59
▲+1.98%
SPCX
$167.01
▲+5.06%
MU
$1,063.10
▼-1.10%
TSLA
$380.36
▲+2.64%
MSFT
$525.60
▲+1.56%
SNDK
$1,707.67
▼-0.72%
INTC
$117.20
▼-1.78%
META
$742.99
▲+2.05%
NVDA
$238.59
▲+1.98%
SPCX
$167.01
▲+5.06%
MU
$1,063.10
▼-1.10%
TSLA
$380.36
▲+2.64%
MSFT
$525.60
▲+1.56%
SNDK
$1,707.67
▼-0.72%
INTC
$117.20
▼-1.78%
META
$742.99
▲+2.05%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
2.935
+0.055 (+1.91%)
Delayed Quote
Updated: 2:20 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
32
33
Next >
Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022
February 16, 2022
Via
Investor Brand Network
Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions
↗
February 14, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)...
Via
Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated as Treatment for Multiple Conditions
February 14, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
February 11, 2022
Via
Investor Brand Network
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
↗
January 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
February 11, 2022
Via
CannabisNewsWire
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs
↗
February 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-...
Via
Benzinga
Lexaria (NASDAQ: LEXX) Technology Shows Promise in Improving Performance of ED Drugs
February 11, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs
February 11, 2022
Via
Investor Brand Network
Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders
↗
February 09, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating...
Via
Benzinga
Lexaria (NASDAQ: LEXX) CEO Summarizes 2021 Milestones in Letter to Shareholders
February 09, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders
February 08, 2022
Via
Investor Brand Network
Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study
↗
February 03, 2022
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study.
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
February 03, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
February 02, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
February 02, 2022
Via
Investor Brand Network
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
February 02, 2022
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast
↗
February 01, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the...
Via
Benzinga
Lexaria (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Tech on EDGE Podcast
February 01, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Technology and Operations on EDGE Podcast
January 31, 2022
Via
Investor Brand Network
Lexaria (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
January 28, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study
January 27, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
January 27, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
January 27, 2022
Via
Investor Brand Network
Lexaria Provides Annual Letter From the CEO
January 27, 2022
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
↗
January 21, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs
January 21, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval
January 20, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
January 20, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
January 20, 2022
Via
CannabisNewsWire
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
32
33
Next >
